
After having been the sole owner of Leo Pharma for 35 years, the Leo Foundation now invites one of the Nordics' largest capital funds, Nordic Capital, into the owner group of Denmark's oldest pharmaceutical company.
This comes with an EUR 450m (USD 534.8m) investment from the Nordic private equity firm which will be put towards supporting Leo Pharma's 2030 strategy. This strategy was made public last year, and its goal is to make the firm a world-spanning leader in medical dermatology.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app